Sagimet Biosciences (SGMT) Competitors $7.56 -0.22 (-2.83%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$7.64 +0.08 (+1.01%) As of 08/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMT vs. TRVI, URGN, IMNM, QURE, SANA, AKBA, PHAT, AMLX, AVXL, and TSHAShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Trevi Therapeutics (TRVI), Urogen Pharma (URGN), Immunome (IMNM), uniQure (QURE), Sana Biotechnology (SANA), Akebia Therapeutics (AKBA), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Anavex Life Sciences (AVXL), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Its Competitors Trevi Therapeutics Urogen Pharma Immunome uniQure Sana Biotechnology Akebia Therapeutics Phathom Pharmaceuticals Amylyx Pharmaceuticals Anavex Life Sciences Taysha Gene Therapies Trevi Therapeutics (NASDAQ:TRVI) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Do insiders & institutionals believe in TRVI or SGMT? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor TRVI or SGMT? In the previous week, Trevi Therapeutics had 4 more articles in the media than Sagimet Biosciences. MarketBeat recorded 7 mentions for Trevi Therapeutics and 3 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.73 beat Trevi Therapeutics' score of 0.64 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TRVI or SGMT more profitable? Sagimet Biosciences' return on equity of -39.88% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -41.44% -38.21% Sagimet Biosciences N/A -39.88%-38.40% Which has higher valuation & earnings, TRVI or SGMT? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.42-17.17Sagimet BiosciencesN/AN/A-$45.57M-$1.83-4.13 Which has more risk and volatility, TRVI or SGMT? Trevi Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.37, suggesting that its stock price is 237% more volatile than the S&P 500. Do analysts recommend TRVI or SGMT? Trevi Therapeutics presently has a consensus price target of $20.11, indicating a potential upside of 178.93%. Sagimet Biosciences has a consensus price target of $25.67, indicating a potential upside of 239.51%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTrevi Therapeutics beats Sagimet Biosciences on 8 of the 14 factors compared between the two stocks. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.02M$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-4.1321.0831.2626.59Price / SalesN/A361.90453.73167.91Price / CashN/A44.6737.7359.36Price / Book1.898.0910.046.68Net Income-$45.57M-$54.08M$3.27B$265.59M7 Day Performance6.33%-0.41%1.34%0.66%1 Month Performance-18.45%6.23%6.13%2.64%1 Year Performance145.45%10.45%41.90%22.36% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences3.0101 of 5 stars$7.56-2.8%$25.67+239.5%+158.0%$253.02MN/A-4.138TRVITrevi Therapeutics2.8628 of 5 stars$7.28-3.6%$20.11+176.3%+144.4%$919.41MN/A-17.3320News CoverageGap UpURGNUrogen Pharma4.5868 of 5 stars$18.50-4.8%$32.00+73.0%+36.6%$899.38M$90.40M-5.57200Positive NewsIMNMImmunome1.615 of 5 stars$9.92-3.7%$22.50+126.8%-36.3%$896.56M$9.04M-3.2240Analyst ForecastQUREuniQure2.4132 of 5 stars$15.55-1.0%$37.45+140.9%+168.1%$861.41M$27.12M-3.97500SANASana Biotechnology3.0485 of 5 stars$3.35-6.4%$8.00+138.8%-48.5%$851.35MN/A-3.16380AKBAAkebia Therapeutics3.8093 of 5 stars$3.03-5.0%$6.75+122.8%+104.6%$845.81M$160.18M-17.82430PHATPhathom Pharmaceuticals2.6243 of 5 stars$11.57-2.9%$17.50+51.3%-23.8%$844.94M$114.04M-2.45110AMLXAmylyx Pharmaceuticals3.3865 of 5 stars$8.50-8.6%$11.75+38.2%+350.7%$829.26M$87.37M-3.40200News CoverageAnalyst ForecastAVXLAnavex Life Sciences3.7634 of 5 stars$9.40-1.4%$44.00+368.1%+56.8%$818.57MN/A-16.4940Analyst ForecastTSHATaysha Gene Therapies3.32 of 5 stars$2.92-2.7%$8.29+183.8%+35.4%$818.39M$8.10M-8.59180 Related Companies and Tools Related Companies Trevi Therapeutics Competitors Urogen Pharma Competitors Immunome Competitors uniQure Competitors Sana Biotechnology Competitors Akebia Therapeutics Competitors Phathom Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors Anavex Life Sciences Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access